摘要
目的:观察芪苈强心胶囊联合沙库巴曲缬沙坦治疗老年扩张型心肌病(DCM)致慢性心力衰竭(CHF)患者的效果。方法:选取2020年1月至2022年12月该院收治的120例老年DCM致CHF患者进行前瞻性研究,采用随机数字表法将其分为对照组(n=60)和观察组(n=60)。对照组给予沙库巴曲缬沙坦治疗,观察组在对照组基础上联合芪苈强心胶囊治疗,比较两组治疗前后心功能指标[心脏指数(CI)、左心室射血分数(LVEF)、心排血量(CO)]水平、炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)]水平、临床疗效、生命质量[生活质量综合评定问卷(GQOLI-74)]评分和不良反应发生率。结果:治疗后,观察组CI、LVEF和CO水平均高于对照组,CRP、IL-6和TNF-α水平均低于对照组,差异有统计学意义(P<0.05);观察组治疗总有效率为96.67%(58/60),高于对照组的83.33%(50/60),差异有统计学意义(P<0.05);治疗后,观察组心理功能、躯体功能、社会功能和物质生活等GQOLI-74评分均高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:芪苈强心胶囊联合沙库巴曲缬沙坦治疗老年DCM致CHF患者可提高治疗总有效率、心功能指标水平和生命质量评分,降低炎性因子水平,效果优于单纯沙库巴曲缬沙坦治疗。
Objective:To observe effects of Qili Qiangxin capsules combined with Sacubitril/Valsartan on elderly patients with chronic heart failure(CHF)caused by dilated cardiomyopathy(DCM).Methods:A prospective study was conducted on 120 elderly patients with CHF caused by DCM admitted to the hospital from January 2020 to December 2022.They were divided into control group(n=60)and observation group(n=60)by using the random number table method.The control group was treated with Sacubitril/Valsartan,while the observation group was treated with Qili Qiangxin capsules on the basis of that of the control group.The levels of cardiac function indicators[cardiac index(CI),left ventricular ejection fraction(LVEF),cardiac output(CO)]and inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and C-reactive protein(CRP)],the clinical efficacy,the quality of life(GQOLI-74)score,and the incidence of adverse reactions between two groups before and after the treatment.Results:After the treatment,the levels of CI,LVEF,and CO in the observation group were higher than those in the control group,the levels of CRP,IL-6,and TNF-αwere lower than those of the control group,and the differences were statistically significant(P<0.05).The total effective rate of the observation group was 96.67%(58/60),which was higher than 83.33%(50/60)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the GQOLI-74 scores of psychological function,physical function,social function,and material life in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Qili Qiangxin capsules combined with Sacubitril/Valsartan can improve the total effective rate,the cardiac function index levels,and the quality of life scores in the elderly patients with CHF caused by DCM,and reduce the levels of inflammatory factors.Moreover,it is superior to single Sacubitril/Valsartan treatment.
作者
张莉
张扬
郭虹
ZHANG Li;ZHANG Yang;GUO Hong(The First Affiliated Hospital of Henan University of Science and Technology Department of Critical Care Medicine,Luoyang 471000 Henan,China;The First Affiliated Hospital of Henan University of Science and TechnologyDepartment of Burns and Thyroid,Luoyang 471000 Henan,China;The First Affiliated Hospital of Henan University of Science and TechnologyDepartment of Gastroenterology,Luoyang 471000 Henan,China)
出处
《中国民康医学》
2023年第18期101-104,共4页
Medical Journal of Chinese People’s Health
关键词
芪苈强心胶囊
沙库巴曲缬沙坦
扩张型心肌病
慢性心力衰竭
心功能
生命质量
炎性因子
Qili Qiangxin capsules
Sacubitril/Valsartan
Dilated cardiomyopathy
Chronic heart failure
Cardiac function
Quality of life
Inflammatory factor
